Research programme: protein tyrosine kinase inhibitors - Takeda
Alternative Names: AP 23864; AP 23994; AP 24163; Inhibitor A; Oncogenic kinase inhibitors - TakedaLatest Information Update: 07 Sep 2021
At a glance
- Originator ARIAD Pharmaceuticals
- Developer Takeda
- Class Small molecules
- Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Protein kinase inhibitors; Protein tyrosine kinase inhibitors; Src-family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda